29 maj: NPinvestor.com A/S: NPinvestor Fondsmæglerselskab A/S gennemfører..
29 maj: OPTAGELSE TIL HANDEL AF CERTIFIKATER UDSTEDT AF NORDEA BANK AB
29-05-2018 12:38:36

Genmab to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

Relateret indhold
Relateret debat
08:14 - 
Mht. investering.   Der er forskel på at lig..
07:52 - 
Min anke er .. og har været .. at Jan nu i 3 &ari..
17 jul - 
Fastholder kursmål på 1900 er vist mere korrekt

Media Release

Copenhagen, Denmark; May 29, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, California at 4:00 PM PDT on June 12, 2018 (1:00 AM CEST on June 13, 2018). A webcast of the presentation will be available on Genmab’s website at http://ir.genmab.com/events.cfm.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication

T: +45 33 44 77 20; M: +45 25 12 62 60; E: rcg@genmab.com

This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Media Release no. 04

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

Primary Logo

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
13 jul
GEN
Det vil være vild fedt,hvis de hoster op med 18 milliarder,det betyder nok et overskud i nærheden af..
9
14 jul
GEN
TheNote har råbt og skreget efter Jan over han ikke får “skrevet nogen aftaler” - men så snart der k..
5
17 jul
GEN
http://borsen.dk/nyheder/virksomheder/artikel/1/365823/salget_af_genmabs_guldaeg_overgaar_alle_forve..
3
12 jul
GEN
Kun tiden kan vise det. Kommer der et nyt vidundermiddel, vil patienter og investorer glæde sig.
3
17 jul
GEN
Der er bare shorterne der holder den nede,den skal nok komme op igen,gemmer mine og tror på 1500.- i..
2
12 jul
GEN
Lander vi Q2 med +500 mio usd inkl ROW tirsdag, så kan det alene give et sus opad... Gav 11% ved Q1...
2
12 jul
GEN
Ja hvad skal man sige til alle de kloge? Lad stilheden svare🤡📈📈📈📈📈
2
17 jul
GEN
Jeffrie sætter kursmål på 1900 !! Run run Genmab. Har naturligvis aktien.   GENMAB/JEFFERIES: DARZAL..
1
17 jul
GEN
511 - hvad sagde jeg
1
13 jul
GEN
The Note har sortsyn hvad angår Genmab alt er dårligt, selv store indtægter som i det her tilfælde.
1

Fondsbørsmeddelelser

#

EuroInvestor: I fokus
#

#

EuroInvestor: I fokus
#

#

EuroInvestor: I fokus
#

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Danske Bank skuffer i andet kvartal og skruer lidt ned for prognosen
2
Aktier/tendens: Danske Bank tager fokus op til forventet grøn åbning
3
Genmab/Jefferies: Darzalex øger tilliden til ledelsens forventninger
4
Aktier/åbning: Danske Bank skraber bunden i generelt negativt C25
5
Ericsson overraskede analytikerne

Relaterede aktiekurser

Genmab A/S 1.136,50 1,9% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Seneste nyheder


Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. juli 2018 14:56:30
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180712.1 - EUROWEB5 - 2018-07-18 14:56:30 - 2018-07-18 14:56:30 - 1 - Website: OKAY